Schedule of Events

8:00-8:45 AM  Breakfast/Registration
8:45-8:55 AM  Opening Remarks
9:00-10:30 AM 1st Slide Session
   Patrick A. Mayes
   Overcoming Drug Resistance of Hypoxic Cancer Cells and Tumors via c-Myc Stabilization by a Novel Class of Small Molecules

   Ann-Marie Chacko
   The Molecular Imaging of HSV1-tk Reporter Gene Expression: New 18F-Labeled Reporter Probes

   Holli Kawadler
   The Molecular Imaging of HSV1-tk Reporter Gene Expression: New 18F-Labeled Reporter Probes

   Jessica N Cleck
   Corticosterone Releasing Factor mRNA Alterations in the Ventral Tegmental Area Following Nicotine Administration

10:30-11:15 PM 1st Poster Session (1-27)

11:15-12:30 PM Luncheon/Free Time

12:45-2:00 PM 2nd Slide Session
   Francheska Colón-
   Disruption of Intramolecular Interactions is Required to Expose Lipid- and Rac-binding Sites of the Rac-GAP a2-chimaerin

   Jennifer Oliver Krasinski
   Pdx1 is required for specification of Ngn3+ pancreatic endocrine progenitors

   Jason Drury
   Expression and characterization of recombinant human 5β-reductase (AKR1D1) and its natural mutant P133R

2:00-2:50 PM 2nd Poster Sessions (28-54)

3:00-4:00 PM The John S. O’Brien Memorial Lecture:
   New Drug Development: The Saga of Carvedilol – Career Opportunities in the Pharmaceutical Industry

   Dr. Robert R. Ruffolo
   President, Wyeth Research and Development (R&D) and Senior Vice President, Wyeth.

4:00-4:50 PM Cheese and wine Reception
5:00 PM Dinner
Dr. Ruffolo is currently President of Research & Development for Wyeth Pharmaceuticals, and Senior Vice President of Wyeth. He joined Wyeth in 2000 as Executive Vice President, responsible for Pharmaceutical Research and Development. Prior to joining Wyeth, Dr. Ruffolo spent 17 years at SmithKline Beecham Pharmaceuticals where he held a number of posts within Research, the last being Senior Vice President and Director of Biological Sciences, Worldwide. Before joining SmithKline Beecham, Dr. Ruffolo spent 6 years at Lilly Research Laboratories as Research Scientist and Chairman of the Cardiovascular Research Committee.

During his tenure at SmithKline Beecham Pharmaceuticals and Lilly Research Laboratories, Dr. Ruffolo played a significant role in the discovery and/or development of a number of marketed products, including Dobutamine (Dobutrex) for the acute management of congestive heart failure, Ropinerole (Requip) for Parkinson's Disease, Eprosartan (Teveten) for hypertension and Carvedilol (Coreg/Kredex) for hypertension, angina, myocardial infarction and congestive heart failure.

Dr. Ruffolo received his B.S. degree in Pharmacy in 1973, and his Ph.D. degree in Pharmacology in 1976, both from The Ohio State University. Thereafter, he was a postdoctoral fellow at the National Institutes of Health. Dr. Ruffolo has authored nearly 500 full length publications and 200 abstracts, and has edited 17 books. He is the Editor-in-Chief of Current Opinions in Pharmacology, and was the Editor-in-Chief and Founder of Pharmacology Reviews and Communications, as well as Editor for Cardiovascular and Renal Drugs for Current Opinion on Investigational Drugs. He has also served as an Editor for the Journal of Pharmacology and Experimental Therapeutics, and the British Journal of Pharmacology. Dr. Ruffolo has served on the editorial boards of 26 international scientific journals.

Dr. Ruffolo has received a number of awards, including the Lorenzini Gold Medal for Biomedical Research (1999), the John Jacob Abel Award in Pharmacology (1988), the Prix Galien Special Commendation for Excellence and Innovation in Research (1996) and the Distinguished Alumni Award from The Ohio State University (1989). In 1997, Dr. Ruffolo was honored by SmithKline Beecham Pharmaceuticals for his pioneering research on Carvedilol (Coreg/Kredex), which radically changed the treatment of congestive heart failure. Most recently, Dr. Ruffolo was
identified by The American Society for Information Science & Technology as a *Highly Cited Scientist* for being among the top one hundred cited Pharmacologists in the world over the past two decades.

Dr. Ruffolo also holds an academic position as Professor of Pharmacology at The Ohio State University. He has been elected or appointed to a number of committees of the International Union of Pharmacology and the American Society of Pharmacology and Experimental Therapeutics, and he has served as Chairman of the International Union of Pharmacology Committee on Receptor Nomenclature and Drug Classification. Dr. Ruffolo has also been recently appointed to the Science & Regulatory Section Executive Committee of the Pharmaceutical Research and Manufacturers of America (PhRMA) and to the Board of Directors of the Biotechnology Industry Organization (BIO).